Next Article in Journal
Comprehensive Analysis Suggests Overlapping Expression of Rice ONAC Transcription Factors in Abiotic and Biotic Stress Responses
Next Article in Special Issue
A Polymorphism at the Translation Start Site of the Vitamin D Receptor Gene Is Associated with the Response to Anti-Osteoporotic Therapy in Postmenopausal Women from Southern Italy
Previous Article in Journal
β-Hydroxybutyric Sodium Salt Inhibition of Growth Hormone and Prolactin Secretion via the cAMP/PKA/CREB and AMPK Signaling Pathways in Dairy Cow Anterior Pituitary Cells
Previous Article in Special Issue
PRRT2 Mutations Are Related to Febrile Seizures in Epileptic Patients
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2015, 16(2), 4281-4305;

Personalization of the Immunosuppressive Treatment in Renal Transplant Recipients: The Great Challenge in “Omics” Medicine

Renal Unit, Department of Medicine, University of Verona, Piazzale A. Stefani, 1, 37126 Verona, Italy
Authors to whom correspondence should be addressed.
Academic Editor: Sabrina Angelini
Received: 22 December 2014 / Revised: 4 February 2015 / Accepted: 9 February 2015 / Published: 17 February 2015
(This article belongs to the Special Issue Pharmacogenetics and Personalized Medicine)
Full-Text   |   PDF [1621 KB, uploaded 17 February 2015]   |  


Renal transplantation represents the most favorable treatment for patients with advanced renal failure and it is followed, in most cases, by a significant enhancement in patients’ quality of life. Significant improvements in one-year renal allograft and patients’ survival rates have been achieved over the last 10 years primarily as a result of newer immunosuppressive regimens. Despite these notable achievements in the short-term outcome, long-term graft function and survival rates remain less than optimal. Death with a functioning graft and chronic allograft dysfunction result in an annual rate of 3%–5%. In this context, drug toxicity and long-term chronic adverse effects of immunosuppressive medications have a pivotal role. Unfortunately, at the moment, except for the evaluation of trough drug levels, no clinically useful tools are available to correctly manage immunosuppressive therapy. The proper use of these drugs could potentiate therapeutic effects minimizing adverse drug reactions. For this purpose, in the future, “omics” techniques could represent powerful tools that may be employed in clinical practice to routinely aid the personalization of drug treatment according to each patient’s genetic makeup. However, it is unquestionable that additional studies and technological advances are needed to standardize and simplify these methodologies. View Full-Text
Keywords: renal transplantation; pharmacogenomics; pharmacogenetics; personalized medicine; immunosuppression renal transplantation; pharmacogenomics; pharmacogenetics; personalized medicine; immunosuppression

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Zaza, G.; Granata, S.; Tomei, P.; Dalla Gassa, A.; Lupo, A. Personalization of the Immunosuppressive Treatment in Renal Transplant Recipients: The Great Challenge in “Omics” Medicine. Int. J. Mol. Sci. 2015, 16, 4281-4305.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top